Updating results

Decision making and mental capacity

In development [GID-NG10009] Expected publication date: 03 October 2018

NICE guideline In development

Vagus nerve stimulation for treatment-resistant depression

In development [GID-IPG10133] Expected publication date: TBC

Interventional procedures guidance In development

Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

In development [GID-IPG10132] Expected publication date: TBC

Interventional procedures guidance In development

Minimally invasive radical hysterectomy for early stage cervical cancer

In development [GID-IPG10131] Expected publication date: TBC

Interventional procedures guidance In development

Functional electrical stimulation to improve muscle strength in non-neurological chronic conditions

In development [GID-IPG10135] Expected publication date: TBC

Interventional procedures guidance In development

Transcranial magnetic stimulation for obsessive-compulsive disorder

In development [GID-IPG10134] Expected publication date: TBC

Interventional procedures guidance In development

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Insertion of an artificial iris implant for aniridia

In development [GID-IPG10130] Expected publication date: TBC

Interventional procedures guidance In development

Deep brain stimulation for refractory epilepsy

In development [GID-IPG10129] Expected publication date: TBC

Interventional procedures guidance In development

Cyanoacrylate glue occlusion for varicose veins

In development [GID-IPG10128] Expected publication date: TBC

Interventional procedures guidance In development

Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

In development [GID-TA10474] Expected publication date: TBC

Technology appraisal guidance In development

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 11 March 2020

Medical technologies guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

In development [GID-TA10479] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535

In development [GID-TA10412] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Technology appraisal guidance In development

PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Technology appraisal guidance In development

Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer [ID1513]

In development [GID-TA10419] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: TBC

Technology appraisal guidance In development

Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia ID1548

In development [GID-TA10416] Expected publication date: 02 December 2020

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Technology appraisal guidance In development

Rezum for treating benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 09 March 2022

NICE guideline In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

In development [GID-TA10452] Expected publication date: TBC

Technology appraisal guidance In development

Workplace health: long-term sickness absence and management

In development [GID-QS10114] Expected publication date: 13 January 2021

Quality standard In development

Internal air: health effects

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Elective joint replacement

In development [GID-QS10090] Expected publication date: 13 January 2021

Quality standard In development

Carers: provision of support for adult carers

In development [GID-QS10128] Expected publication date: 04 December 2020

Quality standard In development

Seven day working

In development [GID-QS10108] Expected publication date: TBC

Quality standard In development

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 26 August 2020

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy ID1536

In development [GID-TA10466] Expected publication date: 15 January 2020

Technology appraisal guidance In development

Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 23 February 2020

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development